• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

New Delhi, Aug. 10

Merck Sharp and Dohme Pharmaceuticals (MSD India) has launched its registered injectable Invanz in India. The wholly owned subsidiary of US drug maker Merck claims the carbapenem antibiotic is a highly effective drug in the treatment of patients who have developed resistance to antibiotics. Invanz is indicated for the treatment of moderate-to-severe infections caused by susceptible isolates of designated micro-organisms. “The launch of Invanz in India is part of Me rck’s continued commitment to introducing medicines recognised by the medical community globally as key products for changing the course of diseases,” said Mr Murali Parthasarathy, Business Unit Director, MSD India. —

Our Bureau

More Stories on : New Products & Services | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Jet, Air India in hot chase for US pie

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line